Can peptides be prescribed by telehealth?
There is no federal telehealth licensing law for non-controlled drugs: the prescriber must be licensed in the state where the patient is located, and each state sets its own rules for establishing the patient relationship. Federal telehealth restrictions come from the Controlled Substances Act (21 U.S.C. 829(e), the Ryan Haight Act) and DEA rules at 21 CFR 1300.04, which generally require an in-person evaluation before a controlled substance is prescribed by telemedicine unless a DEA exception or flexibility applies. None of the peptides in this database are federally scheduled controlled substances, so those rules do not apply to GLP-1 or compounded peptide prescriptions, but they do apply to anything else a telehealth clinic might co-prescribe. [9] [10]
Who regulates peptide compounding?
| Regulator | FDA Center for Drug Evaluation and Research (federal oversight of 503A and 503B compounding) |
|---|---|
| Eligible substances | Follows the federal 503A framework |
Section 503A of the FD&C Act (21 U.S.C. 353a) exempts a compounded drug from new drug approval, labeling, and cGMP requirements only when it is made by a licensed pharmacist or physician for an identified patient on a valid prescription, and only from bulk substances that are components of approved drugs, have a USP or NF monograph, or appear on the 503A bulks list that FDA publishes by rule after Pharmacy Compounding Advisory Committee (PCAC) review. FDA also keeps an interim list of nominated substances: Category 1 (may be compounded while under review), Category 2 (significant safety risks identified, not eligible), and Category 3 (insufficient information). Section 503B outsourcing facilities can compound without patient specific prescriptions but face their own bulks list and cGMP requirements. State pharmacy boards license and inspect the pharmacies themselves; FDA policy and state licensure both have to be satisfied. [1] [2] [3] [4] [5] [6] [7]
Are compounded GLP-1s still legal?
Semaglutide and tirzepatide are FDA approved and available nationwide by prescription. Compounded copies were permitted only while the branded products were on the FDA drug shortage list. FDA declared the tirzepatide shortage resolved on October 2, 2024 and reaffirmed that decision on December 19, 2024 after reconsideration (503A grace period ended February 18, 2025; 503B ended March 19, 2025). FDA declared the semaglutide shortage resolved on February 21, 2025 (503A grace period ended April 22, 2025; 503B ended May 22, 2025). After those dates, a pharmacy may compound a GLP-1 only for a documented patient specific clinical need, such as an allergy to an excipient or a dose strength that is not commercially available, and FDA has warned about products made from salt forms and unapproved dosing. Manufacturer direct-to-consumer cash programs now supply branded vials and pens outside insurance. On April 30, 2026 FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list, after tentatively finding no clinical need for outsourcing facilities to compound them from bulk; that proposal was not final as of September 2026. [3] [8] [15]
Prices by channel: semaglutide cost, tirzepatide cost.
Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.
What is the legal access path?
Access options
Licensed prescriber, in person or by telehealth
Telehealth prescribing of non-controlled peptides is permitted in the United States. The state law we checked does not settle whether a prescription can be issued without a live visit, so expect one.
Compounded peptides must come from a licensed 503A pharmacy or a registered 503B outsourcing facility using an eligible substance.
Branded GLP-1 through a retail or manufacturer pharmacy
FDA approved semaglutide and tirzepatide are available by prescription. Compounded GLP-1 limited; see the GLP-1 section for why.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
What you'll actually find, and how to check
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [18] [19] [20]
No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [3]
What states have done
State boards can act:
- On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [22] Mississippi law
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [23] [24] Louisiana law
Checking the prescriber
Telehealth prescribing of non-controlled peptides is permitted in the United States. The state law we checked does not settle whether a prescription can be issued without a live visit, so expect one. [9] [10] The telehealth rule in full.
Checking the pharmacy
Pharmacies are licensed by state boards, not by FDA. Find your state board’s license search on FDA BeSafeRx: state board of pharmacy license lookups. [21]
If you're going ahead anyway
These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [3]
They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [4] [25] [26]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [21] [27] [28]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [2] [20] [28]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [3] [29] [30] [31] [32] [33]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [3]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [21]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [20]
- Pharmacy: Is this made for me on a prescription written in my name? [2]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [20] [28]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [20]
What is offered for a specific peptide, and what FDA found, is on each peptide page.
Are research use only peptides legal to buy?
Peptides labeled "for research use only" or "not for human consumption" are not exempt from federal drug law when they are marketed or sold for human use. Introducing an unapproved new drug into interstate commerce, or selling a misbranded drug, is a prohibited act under 21 U.S.C. 331 and the new drug approval requirement in 21 U.S.C. 355. FDA has issued warning letters to online sellers marketing peptides such as BPC-157 and other compounds with health claims, and FDA compounding risk alerts describe specific safety problems seen in unapproved peptide products. No state licenses these sellers as pharmacies. [11] [12] [13] [14]
Notes on specific peptides
| Peptide | Note |
|---|---|
| Semaglutide | FDA approved (Ozempic, Rybelsus, Wegovy). Compounded semaglutide lost its shortage-based allowance on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. On April 30, 2026 FDA proposed not to include semaglutide on the 503B bulks list; that proposal was not final as of September 2026. [8] [15] |
| Tirzepatide | FDA approved (Mounjaro, Zepbound). Compounded tirzepatide lost its shortage-based allowance on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. On April 30, 2026 FDA proposed not to include tirzepatide on the 503B bulks list; that proposal was not final as of September 2026. [8] [15] |
| BPC-157 | FDA lists its nomination as withdrawn (page dated April 22, 2026), and it is not on the 503A bulks list. On October 28, 2026 HHS released a draft enforcement discretion policy: HHS will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds single-ingredient BPC-157 by a subcutaneous, intramuscular, oral, or topical route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. It is not an FDA approval or a bulks listing, is not binding, and HHS may revisit it; blends such as Wolverine are not covered. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies. It is not eligible for 503B outsourcing. [1] [4] [7] [16] [17] |
| Ipamorelin | Placed in 503B Category 2 on September 29, 2023 alongside GHRP-2 and GHRP-6, so it cannot be compounded by outsourcing facilities. [4] |
Compare: Wegovy vs Zepbound.
Frequently asked questions
Can any US pharmacy legally compound a peptide?
Only a state-licensed pharmacy (503A) or an FDA-registered outsourcing facility (503B) can compound drugs, and only from bulk substances that are approved drug components, have a USP or NF monograph, or appear on the relevant FDA bulks list. A peptide that FDA has placed in Category 2 or 3, or whose nomination was withdrawn, is not eligible (for Category 1 substances still under review, FDA's interim policy says it does not intend to act against compounding when the ingredient comes from a registered manufacturer with a certificate of analysis and all 503A conditions are met), and states can add their own restrictions on top of the federal rule. Separately, a draft HHS policy released October 28, 2026 says HHS will not take enforcement action against 503A compounding of six peptides (BPC-157, epitalon, KPV, MOTS-c, semax, TB-500) when single-ingredient products meet its conditions; it is not an FDA approval, is not binding, and does not cover blends. [1] [3] [4] [16] [17]
Is compounded semaglutide or tirzepatide still legal in 2026?
Only in narrow circumstances. The shortage-based allowance ended in 2025 (tirzepatide first, then semaglutide), so a pharmacy may now compound a GLP-1 only when a specific patient needs something the approved product cannot provide, such as a different strength or an excipient-free formulation, and never as a routine copy of Wegovy or Zepbound. [8]
Does federal telehealth law stop a clinic from prescribing peptides online?
No. Federal telemedicine rules under the Controlled Substances Act only cover scheduled drugs, and the peptides in this database are not federally scheduled. What matters is the state where the patient is located: the prescriber must hold a license or telehealth registration there and follow that state's rules for establishing a patient relationship. [9] [10]
Are "research use only" peptides legal to buy?
Selling them for human use is a violation of federal drug law: they are unapproved new drugs and, when sold with health claims, misbranded. FDA has issued warning letters to online peptide sellers. Buying them exposes you to products with no identity, purity, or sterility testing and no pharmacist oversight. [11] [12] [13]
What do the PCAC vote and the HHS draft policy on BPC-157 and five other peptides change?
HHS's Appendix B confirms that for BPC-157, TB-500, KPV, MOTS-c, semax, and epitalon, FDA's drug center recommended against listing and the Pharmacy Compounding Advisory Committee voted in favor. On October 28, 2026 HHS released a draft enforcement discretion policy for those six: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds one of them as a single-ingredient product, by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. It is not an FDA approval, does not add them to the 503A bulks list, and is not binding; HHS may revisit it. The notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. Blends, other peptides, and research-use-only products sold for human use are not covered, and state law still applies. [1] [4] [5] [7] [16] [17]
From the blog
- Can you get a GLP-1 through telehealth in your state?
Yes in every state, but the rules for the visit, the prescriber's license, and the pharmacy differ. How state telehealth law shapes GLP-1 access, with state examples.
Sources
Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.
- [1]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [2]21 U.S.C. 353a, Pharmacy compounding (Office of the Law Revision Counsel)
- [3]FDA: Compounding and the FDA, questions and answersFDA
- [4]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
- [5]Federal Register: List of bulk drug substances that can be used to compound drug products in accordance with section 503A (final rule, February 19, 2019)Federal Register, 2019
- [6]FDA: Information for outsourcing facilities (section 503B)FDA
- [7]FDA: Pharmacy Compounding Advisory CommitteeFDA
- [8]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [9]21 U.S.C. 829, Prescriptions (including subsection (e) on controlled substances dispensed by means of the Internet)
- [10]21 CFR 1300.04, Definitions relating to the dispensing of controlled substances by means of the Internet (practice of telemedicine)
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Federal peptide law in the United States. https://peptideagent.ai/legal/federal- HTML link
<a href="https://peptideagent.ai/legal/federal">Federal peptide law in the United States</a>, PeptideAgent, updated October 28, 2026.